珍宝岛：全资子公司获得盐酸莫西沙星片药品注册证书

Core Viewpoint - The announcement by Zhenbao Island (603567) regarding the approval of moxifloxacin hydrochloride tablets by the National Medical Products Administration indicates a significant development in the company's pharmaceutical portfolio, potentially enhancing its market position in the antibacterial drug segment [1] Group 1: Company Developments - Zhenbao Island's wholly-owned subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., has received the drug registration certificate for moxifloxacin hydrochloride tablets [1] - The company has invested approximately 13.64 million RMB in the research and development of this drug [1] Group 2: Market Context - Moxifloxacin hydrochloride is a broad-spectrum antibacterial agent used for treating various bacterial infections [1] - There are currently 24 approved manufacturers of moxifloxacin hydrochloride tablets in China, with a market size reaching 530 million RMB [1] - The production and sales of this drug are subject to significant uncertainties due to national policies and market environment changes [1]